Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
DRMA Stock Chart & Stats
$2.14
-$0.06(-4.41%)
At close: 4:00 PM EST
$2.14
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$1.13 - $23.70
Previous CloseN/A
Volume28.34K
Average Volume (3M)249.42K
Market Cap
$3.26M
Enterprise Value-$3.88M
Total Cash (Recent Filing)$4.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 25, 2026EPS Estimate
-1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding2,835,343
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap-1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.01
Revenue Forecast (FY)$15.00M
Bulls Say, Bears Say
Bulls Say
Operational ReadinessProgress on consumer feedback, finalizing packaging and branding, and selecting a CMO signals operational readiness to support commercialization and may lower execution risk.
Product Launch TimelinePlanned mid-2026 launch of a once-weekly acne treatment kit that pairs an approved OTC active ingredient with proprietary Spongilla could accelerate revenue generation and raise market visibility.
Regulatory StrategyStrategic shift to the FDA OTC monograph pathway is expected to reduce time to market, regulatory complexity, and capital requirements, improving commercialization prospects for Spongilla-based products.
Bears Say
Capital And Regulatory RiskContinuing capital requirements and an extended regulatory timeline for prescription dermatology products prompted the strategic pivot, highlighting funding and approval risks for longer-term growth.
Financial ResultsA wider-than-expected GAAP loss per share, partially driven by a lower share count, could pressure near-term investor sentiment and company valuation.
Revenue Forecast RiskAnalysts apply a 25% revenue risk adjustment to reflect uncertainty around the speed of market adoption for the OTC pivot, which may temper upside expectations.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $1.13 and its highest was $23.70 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $3.26M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 22 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on Nov 14, 2025. The company reported -$1.65 earnings per share for the quarter, missing the consensus estimate of -$1.59 by -$0.06.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Overvalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -1.54.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 2,835,343 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$1.65 in its last earnings report, missing expectations of -$1.59. Following the earnings report the stock price went down -2.229%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Technical Analysis
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―